NasdaqGS:ORICBiotechs
Does ORIC (ORIC) Retaining Rinzimetostat Rights Hint At A High-Conviction, High-Risk Development Strategy?
ORIC Pharmaceuticals previously initiated the Himalayas-1 global Phase 3 registrational trial of rinzimetostat plus Bayer’s NUBEQA (darolutamide) in metastatic castration-resistant prostate cancer patients previously treated with abiraterone, aiming to enroll about 600 patients across 25 countries with radiographic progression-free survival as the primary endpoint.
An interesting aspect of the update is that Bayer is supplying darolutamide at no cost while ORIC retains full global...